- Home
- BOOT vs EWTX Comparison
BOOT vs EWTX Comparison
Compare BOOT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOOT | EWTX |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BOOT | EWTX |
|---|---|---|
| Price | $164.20 | $44.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $223.09 | $39.00 |
| AVG Volume (30 Days) | 700.2K | ★ 954.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $776,854,000.00 | N/A |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $13.91 | N/A |
| P/E Ratio | $69.26 | ★ N/A |
| Revenue Growth | ★ 14.59 | N/A |
| 52 Week Low | $133.18 | $12.31 |
| 52 Week High | $210.25 | $48.40 |
Technical Indicators
Market Signals| Indicator | BOOT | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 56.42 |
| Support Level | $153.59 | $37.81 |
| Resistance Level | $170.63 | $43.93 |
| Average True Range (ATR) | 6.17 | 2.17 |
| MACD | 1.17 | -0.14 |
| Stochastic Oscillator | 85.87 | 96.41 |
Price Performance
Historical ComparisonAbout BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.